Dr. Miksad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
820 Massachusetts Ave
Boston, MA 02118Phone+1 617-638-8000
Summary
- Mission-driven Chief Medical Officer and Digital Health Strategist. I accelerate value in Oncology, Data Science & Virtual Health through patient-centric, physician-led technology and direct multidisciplinary care.
Learn more on LinkedIn: https://www.linkedin.com/in/rebeccamiksadmd/
Explore my scientific research at PubMed: https://tinyurl.com/Miksad-PubMed
Clinical Expertise
- Hepatocellular carcinoma, Cholangiocarcinoma, Hematologic oncology, Hereditary nonpolyposis colon cancer, Cancer genetics, Lynch syndrome, Neuroendocrine tumors, Hereditary nonpolyposis colorectal cancer syndrome, Clinical research, Telemedicine, BRCA gene positivity, Pancreatic ductal carcinoma, Drug development, Combined modality therapy, Medical oncology, Healthcare technology/informatics, Gastrointestinal oncology, Helathcare delivery, Bile Duct Neoplasms, Gallbladder Neoplasms
Education & Training
- Harvard Medical SchoolMMS, Translational Research, 2009 - 2011
- Harvard School of Public HealthMPH, Clinical Effectiveness, 2008
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
- Weill Cornell MedicineClass of 2001
Certifications & Licensure
- MA State Medical License 2004 - 2025
- NY State Medical License 2003 - 2005
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2004 May 01
- Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer Start of enrollment: 2009 Jun 01
- Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.Maureen E Canavan, Xiaoliang Wang, Mustafa S Ascha, Rebecca A Miksad, Timothy N Showalter
JAMA Oncology. 2024-07-01 - Future of Cancer Treatment Guidelines: Integrating Real-World Insights for Equitable Cancer Care.Rebecca A Miksad, Gregory S Calip
JCO Clinical Cancer Informatics. 2024-06-01 - 1 citationsThe US Food and Drug Administration Dual Mandate for Rapid Drug Review and Equity.Rebecca A Miksad, Cleo A Ryals
JAMA Network Open. 2024-05-01
Press Mentions
- Color Health Builds Out Virtual Cancer Clinic, Taking Aim at Employer, Health Plan MarketOctober 18th, 2024
- Robert Winn, Rebecca Miksad, Dana Rollison: We Must Use Real-World Data and Lessons from COVID to Improve Care, Equity in Communities We ServeMay 13th, 2022
- The American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact AwardOctober 25th, 2021
- Join now to see all
Grant Support
- Optimizing Localized Therapy For Primary Liver Cancer: A Clinical Trial And ModelNational Cancer Institute2009–2011
Professional Memberships
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/rebeccamiksadmd/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: